Open AccessAppropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction
Author(s) -
Zhong-guo Fan,
Yang Xu,
Xi Chen,
Ming-yue Ji,
Genshan Ma
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s371506
Subject(s) - myocardial infarction , dapagliflozin , medicine , apoptosis , mitochondrial fission , cardiology , chemistry , endocrinology , diabetes mellitus , biochemistry , type 2 diabetes
Dapagliflozin (DAPA) has been reported to have significant cardiac protective effects on heart failure (HF). However, the dose and time, as well as the underlying mechanisms, for DAPA treatment in acute myocardial infarction (AMI) remain controversial. The aim of this study aimed to assess the efficacy and safety of DAPA treatment along with an increased concentration gradient for AMI and explore the potential mechanisms.